Radient Pharmaceuticals (RPC) Provides Domestic and International Target Market Details for Its Onko-Sure(R) IVD Cancer Diagnostic Test

TUSTIN, CA–(Marketwire – August 11, 2010) –   Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it will present its Onko-Sure in vitro diagnostic (IVD) cancer test to distribution partners at the annual Vietnam International Medical, Hospital and Pharmaceutical exhibition — Vietnam Medi-Pharm Expo, held August 18-21 at the Tan Binh International Exhibition & Convention Center in Ho Chi Minh City, Vietnam. RPC will present at Booth 112 in Hall 3 of the exhibition and convention center.

“The Vietnam Medi Pharm Expo in Ho Chi Minh City is the most prestigious specialized exhibition in Vietnam, with participation from hundreds of local and foreign organizations, groups and enterprises,” commented Dr. Nguyen Quoc Trieu, Minister of Health for Vietnam. “The exhibition offers a premier venue for the medical circle to showcase their latest advancements, achievements, modern technologies, new medicines and healthcare and treatment services.”

Douglas MacLellan, Chairman and CEO of RPC, also commented saying, “We are committed to expanding commercialization efforts for Onko-Sure® in Asia and ASEAN partner countries healthcare markets. Vietnam is an important growth market for RPC and our goal is to leverage this event to increase product sales and distribution in Asia and other ASEAN member states this year.”

Target ASEAN states for RPC include Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam. The total population for ASEAN is approximately 580 million people or 8.7% of the world population. In 2009, this region’s combined nominal gross domestic product (GDP) exceeded more than USD $1.5 trillion, and as a single country, ASEAN ranks as the 9th largest economy worldwide in terms of GDP.

RPC’s Onko-Sure IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection and monitoring of the treatment and/or recurrence of various types of cancer. The test enables physicians and healthcare professionals to effectively detect and/or monitor certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure® is cleared by the US FDA for the treatment and/or recurrence monitoring of colorectal cancer and by Health Canada for the detection, treatment and/or recurrence monitoring of lung cancer. For more information visit www.onko-sure.com.

RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at IR@Radient-Pharma.com or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its Onko-Sure® In Vitro Diagnostic cancer test. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve patient outcomes. Radient Pharmaceutical’s current Onko-Sure cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.